All Cancer articles
-
Article600+ patient-derived cancer models expand the search for drug targets
Hundreds of new patient-derived cancer models could strengthen target validation, identify cancer vulnerabilities and provide more representative systems for preclinical drug discovery.
-
NewsIL-17 identified as potential immunotherapy biomarker in ovarian cancer
A new study has identified IL-17 as a potential biomarker for immunotherapy response in a small subset of clear cell ovarian cancer cases, offering a possible route to personalised treatment for a disease historically resistant to immune-based therapies.
-
NewsExhausted T cells escape tumours to drive lasting cancer immunity
A preclinical study has identified a subset of exhausted, LAG3-expressing T cells capable of migrating out of tumours to establish long-term immune memory, with potential implications for LAG3-targeting cancer immunotherapies.
-
NewsNUS researchers identify molecular switch driving TNBC treatment resistance
Researchers at the National University of Singapore have identified DP103 as a potential molecular master switch sustaining tumour growth, cancer stem cells and treatment resistance in triple-negative breast cancer, with findings suggesting it could serve as a predictive biomarker for the investigational oral therapy RX-5902.
-
NewsPatient-specific brain tumour chip models vascular drug barriers
A microfluidic chip combining patient-derived glioblastoma cells with their tumour vascular environment could give drug developers a more realistic preclinical model for predicting treatment response – and may help explain why genetically similar patients respond differently to the same therapy.
-
NewsAGR2 and FOXM1 identified as prognostic and therapeutic targets in NF-PanNETs
A new study using single-cell RNA sequencing has identified AGR2 as a potential prognostic marker and FOXM1 as a druggable target in non-functional pancreatic neuroendocrine tumours, offering new tools to stratify patients and guide treatment strategies.
-
NewsMulti-target screening refines ADC development for cervical cancer
A large-scale transcriptomic study has pinpointed distinct cell-surface targets for antibody-drug conjugate development across cervical cancer subtypes, revealing how tissue-of-origin comparisons and subpopulation analysis can uncover targets missed by conventional screening approaches.
-
NewsNanomedicine for glioblastoma: overcoming the blood-brain barrier
A new review published in Chinese Neurosurgical Journal examines how nanoscale drug delivery systems could help overcome one of the most persistent obstacles in glioblastoma treatment – getting therapeutics across the blood–brain barrier and into tumour tissue.
-
ArticleFibroblast barrier linked to immunotherapy resistance in colorectal cancer
Why do some colorectal cancers resist immunotherapy? Analysis of patient tumour samples has identified a population of fibroblasts that could help explain treatment resistance.
-
NewsHow CAR T cells are being engineered to target tumour’s ‘soft spot’
A preclinical study published in Nature Biomedical Engineering describes a synthetic biology approach that converts the physical softness of cancer cells into a targetable signal for CAR-T immunotherapy, potentially addressing a key resistance mechanism in solid tumours.
-
NewsAI identifies experimental drug targeting undruggable cancer protein
Mayo Clinic researchers have used AI to screen nearly 40,000 compounds and identify a small molecule inhibitor targeting GIPC1, a protein previously considered undruggable, with preclinical results showing slowed tumour growth and enhanced chemotherapy response.
-
NewsTargeting the roots of head and neck cancer: Why MDA-9 matters
A small molecule inhibitor developed at Virginia Commonwealth University has demonstrated the ability to eliminate cancer stem cells and reverse cisplatin resistance in preclinical models of head and neck squamous cell carcinoma, offering a potential new strategy to address one of oncology’s most persistent clinical challenges.
-
NewsTriple drug combination targets cancer and senescent cells simultaneously
A three-drug combination targeting shared metabolic vulnerabilities in cancer and senescent cells has improved physical performance and extended survival in aged mice, whilst avoiding the thrombocytopenia associated with existing navitoclax-based regimens.
-
ArticleUnderstanding the toxicology endpoints that matter in ADC development
Antibody-drug conjugates (ADCs) present unique toxicology challenges. Learn which endpoints matter most, how they inform development decisions and why they are essential for building a robust nonclinical safety strategy.
-
ArticleInside one of the most comprehensive human proteome atlases to date
Understanding where proteins are expressed throughout the body is critical for selecting better drug targets. Here’s how a new human proteome atlas could improve target selection, predict toxicity and support drug repurposing.
-
NewsHow dendritic cells organise tumour immunity – and why drug developers should take notice
A new study published in Science identifies a specialised dendritic cell subset as the cellular architects behind tertiary lymphoid structures, offering a potential new target for boosting anti-tumour immunity and converting immunologically cold tumours into treatment-responsive ones.
-
NewsAmino acid sensor discovery could unlock new targeted cancer therapies
Researchers have uncovered how cells sense amino acids and activate the mTORC1 growth pathway, identifying LARS1 phosphorylation as a critical upstream switch with implications for more precise cancer drug development.
-
ArticleHow spatial biology is tracking antibody drugs inside tumours
Many antibody therapies fail to reach all cancer cells within solid tumours. Researchers have developed a spatial biology technique that maps antibody distribution alongside the tumour microenvironment to investigate why.
-
NewsNew bispecific T cell engager platform targets ovarian cancer in preclinical studies
Scientists at The Wistar Institute have engineered a DNA-delivered bispecific T cell engager using a ‘knob-into-hole’ antibody platform, demonstrating improved persistence and dual-antigen targeting in preclinical ovarian cancer models.
-
NewsTumour organoids may expand access to targeted cancer drugs
Two studies from Weill Cornell Medicine demonstrate that patient-derived tumour organoids can accurately replicate cancers long-term and incorporate immune microenvironments, offering new potential for personalised treatment selection.